暂无推荐供应商。我要出现这里
化源商城直购
[1]. Y. Cheng, et al. 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Immuno-Oncology and Technology. DECEMBER 01, 2022.